Insider Buying: Forte Biosciences, Inc. (NASDAQ:FBRX) CFO Purchases 22,514 Shares of Stock

Forte Biosciences, Inc. (NASDAQ:FBRX) CFO Antony A. Riley purchased 22,514 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average price of $5.55 per share, with a total value of $124,952.70. Following the purchase, the chief financial officer now owns 30,776 shares in the company, valued at $170,806.80. This trade represents a 272.50 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Forte Biosciences Stock Performance

Forte Biosciences stock traded up $0.36 during trading hours on Friday, reaching $16.00. 395,225 shares of the stock were exchanged, compared to its average volume of 142,173. The stock has a market cap of $23.36 million, a P/E ratio of -0.88 and a beta of 0.04. The firm’s 50 day moving average is $5.73 and its 200 day moving average is $2.58. Forte Biosciences, Inc. has a 52-week low of $4.11 and a 52-week high of $21.25.

Analyst Ratings Changes

Separately, Chardan Capital raised their price target on Forte Biosciences from $3.00 to $64.00 and gave the stock a “buy” rating in a report on Friday, November 15th.

About Forte Biosciences

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.